Paper II
Question
Prasad, 40-year-man weighing 60 kg suffering from chronic cough with expectoration and fever was diagnosed to have cavitary pulmonary tuberculosis. (
- (a)Classify the drugs used in the treatment of tuberculosis. ( 4 mark(s)
- (b)Discuss in detail on the mechanism of action and adverse effects of first line antitubercular drugs. ( 8 mark(s)
- (c)Add a note on the drug therapy of Multi Drug Resistant tuberculosis 3 mark(s)
Answer
a) Classification of antitubercular drugs
| Line | Drugs |
|---|---|
| First-line | Isoniazid, Rifampicin, Pyrazinamide, Ethambutol, Streptomycin |
| Second-line | Fluoroquinolones, Aminoglycosides (Kanamycin, Amikacin), Ethionamide, Cycloserine, PAS, Bedaquiline, Linezolid |
b) Mechanism of action and adverse effects of first-line drugs
- Isoniazid — a prodrug, activated by mycobacterial KatG, inhibits InhA (mycolic acid synthesis), bactericidal against actively dividing organisms. AE: peripheral neuropathy (prevented by pyridoxine), hepatotoxicity.
- Rifampicin — inhibits bacterial RNA polymerase, active against both dividing and semi-dormant organisms. AE: hepatotoxicity, orange-red body fluid discoloration, potent CYP450 induction.
- Pyrazinamide — active specifically in the acidic intracellular/caseous environment, mechanism incompletely understood. AE: hepatotoxicity, hyperuricemia.
- Ethambutol — inhibits arabinosyl transferase (arabinogalactan synthesis), bacteriostatic. AE: optic neuritis (dose-related, red-green color blindness — the specific reason visual acuity/color vision monitoring is recommended).
- Streptomycin — aminoglycoside, inhibits bacterial protein synthesis (30S ribosomal subunit). AE: ototoxicity, nephrotoxicity.
c) Drug therapy of MDR-TB MDR-TB (resistant to at least isoniazid and rifampicin) requires a longer, more toxic second-line regimen combining fluoroquinolones, second-line injectables, and other agents (ethionamide, cycloserine, PAS), often supplemented with newer drugs (bedaquiline, linezolid), for 18-24 months (or shorter regimens where available), with poorer outcomes and greater toxicity than standard therapy.

